Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CABA Stock Forecast 2025-2026
$1.73
Current Price
$167.74M
Market Cap
Buy 9
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to CABA Price Targets
+1,518.5%
To High Target of $28.00
+767.1%
To Median Target of $15.00
+73.4%
To Low Target of $3.00
CABA Price Momentum
-13.1%
1 Week Change
-8.0%
1 Month Change
-79.2%
1 Year Change
-23.8%
Year-to-Date Change
-81.6%
From 52W High of $9.41
+75.5%
From 52W Low of $0.99
📊 TOP ANALYST CALLS
Did CABA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Cabaletta Bio is one of their latest high-conviction picks.
Latest CABA Stock Price Targets & Analyst Predictions
Based on our analysis of 15 Wall Street analysts, CABA has a bullish consensus with a median price target of $15.00 (ranging from $3.00 to $28.00). The overall analyst rating is Strong Buy (8.9/10). Currently trading at $1.73, the median forecast implies a 767.1% upside. This outlook is supported by 9 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Michael Ulz at Morgan Stanley, projecting a 1,518.5% upside. Conversely, the most conservative target is provided by Derek Archila at Wells Fargo, suggesting a 73.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CABA Analyst Ratings
9
Buy
2
Hold
0
Sell
CABA Price Target Range
Low
$3.00
Average
$15.00
High
$28.00
Current: $1.73
Latest CABA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CABA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 11, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $25.00 |
| May 16, 2025 | Guggenheim | Yatin Suneja | Buy | Maintains | $25.00 |
| May 16, 2025 | Citigroup | Samantha Semenkow | Buy | Maintains | $13.00 |
| May 15, 2025 | Guggenheim | Yatin Suneja | Buy | Maintains | $25.00 |
| Apr 1, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $25.00 |
| Apr 1, 2025 | Wells Fargo | Derek Archila | Equal-Weight | Maintains | $3.00 |
| Apr 1, 2025 | Morgan Stanley | Michael Ulz | Overweight | Maintains | $22.00 |
| Apr 1, 2025 | UBS | Trung Huynh | Buy | Maintains | $7.00 |
| Apr 1, 2025 | Guggenheim | Yatin Suneja | Buy | Reiterates | $23.00 |
| Feb 18, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $25.00 |
| Jan 17, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $25.00 |
| Dec 20, 2024 | Evercore ISI Group | Gavin Clark-Gartner | In-Line | Downgrade | $6.00 |
| Dec 19, 2024 | Wells Fargo | Derek Archila | Equal-Weight | Downgrade | $6.00 |
| Nov 18, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $25.00 |
| Nov 15, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $25.00 |
| Nov 15, 2024 | Wells Fargo | Derek Archila | Overweight | Maintains | $12.00 |
| Oct 10, 2024 | UBS | Trung Huynh | Buy | Initiates | $10.00 |
| Sep 17, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $25.00 |
| Aug 12, 2024 | Evercore ISI Group | Gavin Clark-Gartner | Outperform | Maintains | $15.00 |
| Aug 12, 2024 | Wells Fargo | Derek Archila | Overweight | Maintains | $20.00 |
Cabaletta Bio Inc. (CABA) Competitors
The following stocks are similar to Cabaletta Bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CABA
Cabaletta Bio
mkt cap
100.98M
Cabaletta Bio Inc. (CABA) Financial Data
Cabaletta Bio Inc. has a market capitalization of $167.74M with a P/E ratio of -0.7x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -73.9%.
Valuation Metrics
Market Cap
$167.74M
Enterprise Value
$-8,401,117
P/E Ratio
-0.7x
PEG Ratio
-0.8x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+150.2%
Current Ratio
4.0x
Debt/Equity
23.7x
ROE
-73.9%
ROA
-41.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cabaletta Bio Inc. (CABA) Business Model
About Cabaletta Bio Inc.
What They Do
Biotechnology company focusing on T cell therapies.
Business Model
Cabaletta Bio Inc. generates revenue through the discovery and development of engineered T cell therapies aimed at treating autoimmune diseases. By utilizing its proprietary CABA technology platform, the company manipulates patients' immune cells to create targeted therapies, addressing unmet medical needs in areas such as dermatology, rheumatology, and neurology.
Additional Information
Headquartered in Philadelphia, Cabaletta Bio is at the forefront of immunotherapy innovation and is closely monitored by stakeholders in the medical community, indicating strong potential for growth in the expanding market of cellular therapies for complex immune-mediated disorders.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
163
CEO
Dr. Steven A. Nichtberger M.D.
Country
United States
IPO Year
2019
Website
www.cabalettabio.comCabaletta Bio Inc. (CABA) Latest News & Analysis
Latest News
Quick Summary
Seven of eight myositis patients showed significant TIS responses after stopping immunomodulators, with sustained effects during follow-up, even while tapering steroids.
Why It Matters
Positive outcomes in myositis treatment suggest potential for new therapies, boosting investor confidence in biotech stocks and increasing market interest in immunomodulator alternatives.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cabaletta Bio, Inc. has launched an underwritten public offering of common stock and warrants, with a 30-day option for underwriters to purchase an additional 15%. All securities will be sold by the company.
Why It Matters
Cabaletta Bio's public offering indicates a need for capital, which could affect share dilution. Investors may assess potential impacts on stock value and the company's future growth prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cabaletta Bio, Inc. announced a public offering of 39.2 million shares and warrants, priced at $2.00 per share, with an option for underwriters to buy 15 million additional shares.
Why It Matters
Cabaletta Bio's public offering dilutes existing shares but raises funds for development. The exercise prices of the warrants suggest potential future capital influx if investors exercise them.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cabaletta Bio's CAR T-cell therapy demonstrates durable efficacy in autoimmune diseases. A BLA submission for myositis is planned for 2027, but financial risks suggest potential dilution before commercialization.
Why It Matters
Cabaletta Bio's CAR T-cell therapy shows promise in autoimmune diseases, but significant financial risks and potential dilution may impact future valuations and investor confidence.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Cabaletta Bio, Inc. (Nasdaq: CABA) will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2025, at 11:05 a.m. ET in New York.
Why It Matters
Cabaletta Bio's participation in a major healthcare conference highlights its commitment to innovation in autoimmune therapies, potentially attracting investor interest and influencing stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cabaletta Bio's RESET-Myositis trial added two cohorts of ~15 patients. RMAT designation granted for rese-cel in myositis. BLA submission expected in 2027, with FDA discussions for SLE and systemic sclerosis in 2025.
Why It Matters
Cabaletta Bio's progress in the RESET-Myositis trial and RMAT designation for rese-cel signals potential FDA approval, addressing a significant unmet need in autoimmune treatments, impacting stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CABA Stock
What is Cabaletta Bio Inc.'s (CABA) stock forecast for 2025?
Based on our analysis of 15 Wall Street analysts, Cabaletta Bio Inc. (CABA) has a median price target of $15.00. The highest price target is $28.00 and the lowest is $3.00.
Is CABA stock a good investment in 2025?
According to current analyst ratings, CABA has 9 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.73. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CABA stock?
Wall Street analysts predict CABA stock could reach $15.00 in the next 12 months. This represents a 767.1% increase from the current price of $1.73. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cabaletta Bio Inc.'s business model?
Cabaletta Bio Inc. generates revenue through the discovery and development of engineered T cell therapies aimed at treating autoimmune diseases. By utilizing its proprietary CABA technology platform, the company manipulates patients' immune cells to create targeted therapies, addressing unmet medical needs in areas such as dermatology, rheumatology, and neurology.
What is the highest forecasted price for CABA Cabaletta Bio Inc.?
The highest price target for CABA is $28.00 from Michael Ulz at Morgan Stanley, which represents a 1,518.5% increase from the current price of $1.73.
What is the lowest forecasted price for CABA Cabaletta Bio Inc.?
The lowest price target for CABA is $3.00 from Derek Archila at Wells Fargo, which represents a 73.4% increase from the current price of $1.73.
What is the overall CABA consensus from analysts for Cabaletta Bio Inc.?
The overall analyst consensus for CABA is bullish. Out of 15 Wall Street analysts, 9 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $15.00.
How accurate are CABA stock price projections?
Stock price projections, including those for Cabaletta Bio Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 5:43 PM UTC